This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Philip Morris Beats Estimates in Q1 Earnings: ETFs in Focus
by Yashwardhan Jain
Philip Morris beat expectations for both revenues and earnings, driven by robust pricing and increased product volumes.
Philip Morris' Q3 Earnings Beat Puts ETFs in Focus
by Yashwardhan Jain
Look into ETFs with an exposure in PM, as the tobacco company reports robust Q3 earnings.
5 ETFs to Make the Most of Philip Morris's Q2 Earnings Beat
by Yashwardhan Jain
Philip Morris beat both earnings and revenue estimates in the second quarter. Look into some ETFs to capitalize.
Roundhill's Cannabis ETF (WEED) Launch Seems Timely
by Sanghamitra Saha
Roundhill Investments recently announced the launch of its own cannabis ETF, namely Roundhill Cannabis ETF (WEED).
Cannabis ETFs to Surge on Banking Bill Approval in House
by Sanghamitra Saha
On Apr 19, the U.S. House of Representatives okayed legislation that would allow banks to provide services to cannabis companies in states where it is legal.
Cannabis On a Roll: Guide to ETF Investing
by Sanghamitra Saha
Shares of cannabis-related stocks and ETFs continue to be in good shape after a solid run last year.
Should You Invest in Marijuana Stocks & ETFs Now?
by Neena Mishra
CNBC's cannabis expert Tim Seymour discusses the outlook for the industry.
Cannabis ETFs Spike on Jazz-GW Pharma Deal
by Sweta Killa
Jazz Pharmaceuticals (JAZZ) agreed to buy cannabinoid drug company GW Pharmaceuticals (GWPH) for $7.2 billion in cash and stock that has strengthened the bullish case for the cannabis industry.
ETFs to Buy as Tilray-Aphria Merger Creates Cannabis Giant
by Sweta Killa
Investors seeking to take advantage of the merger deal between Tilray and Aphria could invest in any of the cannabis ETFs.
Cannabis ETFs Set to Soar in 2021 on More U.S. Legalization
by Sweta Killa
Given the prospect of loosening regulations and increased legalization, cannabis stocks are set to soar in 2021.
Why Cannabis Stocks & ETFs Are Soaring
by Neena Mishra
Marijuana stocks are rising on hopes of favorable regulatory environment
How Cannabis ETFs Beat S&P 500 Past Month
by Sanghamitra Saha
Cannabis stocks and ETFs jumped last week. Here's why.
Are Marijuana Stocks, ETFs Poised for Upbeat Earnings?
by Sanghamitra Saha
"Essential Business" status tagged with marijuana selling amid lockdowns should have helped cannabis stocks and ETFs in the first quarter.
Are Marijuana Stocks & ETFs Coronavirus-Proof?
by Sanghamitra Saha
Marijuana companies are witnessing robust demand amid the coronavirus outbreak. Time to buy some earlier-battered marijuana stocks and ETFs?
What Do Canopy Earnings Say About Cannabis ETFs?
by Sanghamitra Saha
Solid earnings drive Canopy Growth stock and boost the industry as a result. Is it right time to buy marijuana ETFs?
Cannabis ETFs Are Soaring in 2020: Will the Trend Continue?
by Sweta Killa
With a greater legislative push to legalize recreational marijuana, cannabis ETFs are soaring to start the year and are likely to continue doing so.
What's Ahead for Marijuana ETFs After a Dismal Show in 2019?
by Sanghamitra Saha
Marijuana ETFs hit a high in 2018 only to experience a bloodbath in 2019. Let's see what lies in store for the space in 2020.
Best & Worst ETF Areas of Last Week
by Sanghamitra Saha
Inside the ETF gainers and losers of last week.
Cannabis ETFs in Focus on Thanksgiving Weekend
by Sweta Killa
Cannabis spending rises over the Thanksgiving holiday period, especially Green Wednesday as well as on Black Friday.
Marijuana ETFs Bounce Back: Can the Rally Last?
by Sanghamitra Saha
Passing of a legalization bill by a U.S. congressional committee boosted the battered marijuana ETF space lately.
Can Bill Hopes Relieve Earnings-Induced Pain in Pot ETFs?
by Sanghamitra Saha
A wave of disappointing earnings caused a bloodbath in marijuana ETFs last week. However, talks of an end to the federal embargo on marijuana could turn this segment around.
Top ETF Stories of October
by Sanghamitra Saha
Announcement of phase-one trade deal, Fed rate cut, moderate earnings, marijuana crash and Brexit extension regulated the ETF world in October.
Should You Buy the Dip in Marijuana ETFs Ahead of Earnings?
by Sanghamitra Saha
Hexo's downbeat results weigh on marijuana space but many key pot companies are likely to beat in November. This could provide a good entry points to pot ETFs.
Top and Flop ETFs of October
by Sanghamitra Saha
Signs of some progress in the U.S.-China trade relation, Brexit doldrums, oil price rally and mixed earnings pulled the stings of the market movement and made these ETFs winners and losers.
Reefer Madness: Breaking Down The Current Cannabis Industry
by Panel Of Zacks Experts
Today we are joined by David Borun to discuss everything we need to know about the marijuana industry.